VERAXA Biotech AG (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The data, presented as the company prepares for the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D), showed that the BiTAC-ADC platform could distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids.
The BiTAC-ADC platform is part of VERAXA’s proprietary BiTAC approach, which aims to enhance the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline that includes ADCs, T-cell engagers (TCEs), and other antibody-based formats. The new data marks a step forward in validating the BiTAC technology, though the platform remains in early development.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The company is now positioned to engage with potential pharmaceutical and biotechnology partners at the BIO International Convention, where it will present both its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations.
The ability to selectively target cancer cells while sparing healthy tissue is a critical goal in oncology, as it could reduce side effects and improve treatment efficacy. VERAXA’s BiTAC technology addresses this by ensuring that the therapeutic payload is released only within the tumor microenvironment, potentially overcoming limitations of traditional ADCs. The new in vitro results provide early evidence of this selectivity, though further studies, including in vivo testing, will be necessary to confirm the platform’s potential.
Investors and industry observers are watching VERAXA closely as it advances its pipeline. The company’s newsroom (https://nnw.fm/VRXA) provides updates on its progress. With the BiTAC-ADC platform entering the spotlight, VERAXA is positioning itself as a player in the next generation of cancer therapies, leveraging its proprietary technology to potentially fill gaps in current treatment options.
